Cognitive Behavioural Therapy of Early Dementia

Cognitive Behavioural Resource-based Therapy of Early Dementia in the Everyday Setting

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00735046

Acronym

KORDIAL

Enrollment

200

Registered

2008-08-14

Start date

2008-04-30

Completion date

2010-04-30

Last updated

2011-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Keywords

Early dementia in Alzheimer's disease (MMSE ≥ 21)

Brief summary

A randomized, controlled, parallel-group trial to evaluate the efficacy of a cognitive behavioral therapy for patients with early dementia.

Detailed description

The KORDIAL study is a randomized, controlled, parallel-group trial evaluating the efficacy of a cognitive behavioral therapy for patients at the early stage of Alzheimer's disease. The 3-month experimental intervention consists of 12 individual sessions with regular involvement of carers or other patient proxies. Strategies for improving the patient's coping ability and for enhancing their psychological well-being are combined. The primary outcome criterion is functioning in the everyday context after completion of the intervention and after another 6 months. The control condition will be treatment as usual. The study will be conducted in 5 university outpatient units and in 5 specialist offices.

Interventions

BEHAVIORALCognitive behavioral therapy for early Alzheimer's disease

12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.

OTHERControl

Patients and proxies who are assigned to treatment as usual

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

* Mild dementia (MMSE \> 21) in Alzheimer's disease (ICD-10), proxy available

Exclusion criteria

* Acute of unstable psychiatric or physical disease, proxy unavailable * Participation in another trial

Design outcomes

Primary

Measure	Time frame
Functional ability in the everyday context	Baseline, post treatment, 6 months post treatment

Secondary

Measure	Time frame
Quality of life, depression, neuro-psychiatric symptoms	Same as for primary outcome

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026